Clinical outcome analysis
Supplementary Figure 1 . Flowchart summary of the experimental design and step-wise analyses employed in this study. In this study, two independent cohorts were used for discovery (upper) and validation (bottom). There were a total of 50 OSCC patients in the 1st cohort (Supplementary Table S1 ). WES were carried out for all 50 pairs of tumor tissues and matched PBMC cells and RNA-Seq were carried out for 39 paired tumor/matched normal tissues. We validated a subset of SNVs found in WES with Ion AmpliSeq comprehensive cancer panel (CCP) for 49 paired tumor/matched PBMC samples. A3B deletion polymorphism in the first cohort was verified by PCR-based genotyping analysis. Mutation signatures, copy number variations and expression profiles were analyzed on the basis of WES and RNASeq data. To further confirm the upregulation of A3A and A3B expression in OSCC samples and inspect the consequence of this expression alteration, we further included another 188 OSCC patients, from which we obtained RNA from 188 paired tumor/normal matched tissues and 143 PBMC DNA samples. We then examined the relationship between the clinical outcome and expression levels of A3A and A3B. 0   10   20   30   40   50   60   70   TP53  TTN  HYDIN  FAT1  MUC16  COL22A1  SYNE1  NOTCH1  CSMD1  RYR2  CSMD3  LRP1B  PIK3CA  PKHD1  KIAA1324  CASP8  PKHD1L1  ABCC9  GPR98  CSMD2  PAXBP1  PREX2  RBFOX1  DNAH5 Glutathione-dependent formaldehyde-activating enzyme
LAMA3 ( Supplementary Figure . Cosine similarity for mutational signatures found in cancers reported to have APOBEC-associated mutation signature. After mutation signatures were identified, cosine similarity was used to represents the extent of similarity to particular signatures as defined previously (see on-line Methods). The heatmap depicts cosine similarity result (score ranging from 0 to 1) on the mutation spectrums of OSCC-India, OSCC-TCGA, HNSC, BLCA, BRCA, CESC, ESCA, L SC, and L AD. OSCC-TCGA, a subset of OSCC from HNSC in TCGA. HNSC, head and nec squamous cell carcinoma. BLCA, bladder urothelial carcinoma. BRCA, breast invasive carcinoma. CESC, cervical squamous cell carcinoma. ESCA, esophageal carcinoma. L SC, lung squamous cell carcinoma. L AD, lung adenocarcinoma.
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